Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pan...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother
Main Authors: Royal, Richard E., Levy, Catherine, Turner, Keli, Mathur, Aarti, Hughes, Marybeth, Kammula, Udai S., Sherry, Richard M., Topalian, Suzanne L., Yang, James C., Lowy, Israel, Rosenberg, Steven A.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322622/
https://ncbi.nlm.nih.gov/pubmed/20842054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181eec14c
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki